Live prices from 0 SA suppliers, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
We haven't found any suppliers listing this peptide yet. Check back soon as we update our database regularly.
We haven't found any suppliers listing this peptide yet. Check back soon as we update our database regularly.
More ways to compare Abaloparatide
Different views of the same live SA pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
PTHrP Analog | Anabolic Bone-Building Agent
Abaloparatide is an FDA-approved anabolic bone-building agent and synthetic analog of parathyroid hormone-related protein (PTHrP). It selectively activates the PTH1 receptor to stimulate new bone formation while minimizing bone resorption. In the phase III ACTIVE trial, abaloparatide showed superior BMD increases at the hip compared to teriparatide, with substantial fracture risk reduction. It was approved in the US in 2017 and EU in 2022 for postmenopausal women and men with osteoporosis at high fracture risk.
Abaloparatide works through selective activation of the parathyroid hormone 1 receptor (PTH1R), a G protein-coupled receptor expressed on osteoblasts and osteocytes. It preferentially binds to the RG (relaxed, G-protein-coupled) conformational state of PTH1R, which elicits a transient downstream cyclic AMP signaling response favoring anabolic bone formation over resorption. This selective binding pattern produces more bone-building activity with less hypercalcemic effect compared to native PTH. The result is increased cortical and trabecular bone volume, density, and improved microarchitecture.
C174H299N56O49 - 41% homology to PTH(1-34), 76% homology to PTHrP(1-34)
FDA-approved for postmenopausal women with osteoporosis at high risk for fracture or who have failed other therapies.
FDA-approved for men with osteoporosis at high risk for fracture or intolerant to other treatments.
Phase III trials demonstrated substantial reduction in vertebral and nonvertebral fractures.
ACTIVExtend trial showed benefits of abaloparatide followed by alendronate for maintained bone protection.
Abaloparatide is administered as a once-daily subcutaneous injection in the periumbilical (around the navel) region of the abdomen. It comes in pre-filled pen devices (Tymlos). Cumulative lifetime use is limited to 2 years due to theoretical osteosarcoma risk observed in rodent studies. A transdermal patch formulation is also in development.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Osteoporosis treatment | 80 mcg | Once daily | SubQ (periumbilical abdomen) |
ACTIVExtend trial showed sequential abaloparatide then alendronate maintained and extended bone benefits.
Adequate calcium (500-1000mg) and vitamin D (400-800 IU) supplementation recommended during therapy.
Do not use concurrently; both are PTH receptor agonists. Choose one or use sequentially.
Different mechanisms; no known interactions.
Different mechanisms; no known interactions.
Bone formation markers increase; initial BMD changes begin
Significant BMD increases at spine, hip, and femur
Continued bone density improvements; fracture risk reduction
Maximum benefits in ACTIVE trial; substantial fracture reduction
Transition to maintenance therapy (e.g., bisphosphonates) recommended
JAMA · Miller PD, Hattersley G, Riis BJ, et al.
Abaloparatide showed substantial reduction in vertebral fractures and greater BMD increases at spine, hip, and femur compared to placebo and teriparatide.
Mayo Clinic Proceedings · Cosman F, Miller PD, Williams GC, et al.
18 months abaloparatide followed by alendronate significantly reduced vertebral and nonvertebral fractures.
Journal of Clinical Endocrinology and Metabolism · Leder BZ, O'Dea LS, Zanchetta JR, et al.
Significant BMD increases at 40 and 80 mcg doses; abaloparatide showed superior anabolic effects on hips vs teriparatide.
Cureus · Tella SH, Kommalapati A, Correa R
Abaloparatide preferentially binds RG conformational state of PTH1R, producing more anabolic bone effects.
Be the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.